Press "Enter" to skip to content

Basal Insulin (Long-Acting Insulin) Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024

Basal

The “Basal Insulin (Long-Acting Insulin) Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Basal Insulin (Long-Acting Insulin) market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Basal Insulin (Long-Acting Insulin) market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • The global basal insulin market is expected to register a CAGR of 8.2% during the forecast period of 2019–2024, the market is estimated to reach USD 11.4 billion by 2019.
  • Diabetes is generally considered as a lifestyle disease. Over time, incidences of the disease have increased, with the increase in population around the world.
  • Approximately, 100 million people around the world need insulin, including all the people living with Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
  • Basal insulin is the most widely used insulin among diabetic patients because of its long-acting effect. Lantus tops the market, and the segment had more than 50% market share in 2017. Many countries have come up with the biosimilars of insulin since 2015.
  • Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle to prevent complications.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999763

    In Basal Insulin (Long-Acting Insulin) Market Report, Following Companies Are Covered:

  • Novo Nordisk AS
  • Sanofi Aventis
  • Eli Lilly
  • Biocon
  • Julphar
  • Exir
  • SEDICO
  • Wockhardt

    Basal Insulin (Long-Acting Insulin) Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • The market is segmented by product (lantus, levemir, tresiba, toujeo, basaglar, and biosimilar glargines) and geography.

    Reasons for Buying Basal Insulin (Long-Acting Insulin) Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999763

    Key Market Trends: – Insulin Glargine Market Access has Widened

    Lantus (insulin glargine) is the first long-acting insulin brought into the market by Sanofi. The product was approved for medical use in the United States in 2000.
    Lantus’ reach was high among patients across different geographical regions, and it is one of the most top-selling drugs for Sanofi, which is exported to more than 100 countries.
    As of 2015, Lantus market share was around USD 7 billion. However, patent protection for Lantus expired in most countries in 2015. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the United States) and Abasaglar (as a biosimilar in the European Union).
    In 2015, Sanofi launched the extended version of Lantus as Toujeo with 300U/mL strength.
    In less stringent regulatory environments, such as India, China, Mexico, and Peru, several biosimilar insulin already exist at lower prices. In India, a glargine biosimilar was first introduced by Biocon in 2011 at a cost that was 40% lower than Lantus. More recently, Lupin Ltd, in agreement with LG Life Sciences, launched its biosimilar ‘Basugine’ in 2014.
    In China, follow-on biologics Basalin (Gan and Lee Pharmaceuticals, Beijing) ranked second in the Chinese glargine market, and occupied a 40% share, after Lantus, in 2017.

    The United States Leads the Global Basal Insulin Market

    In the global basal insulin market, the United States held 65.6% market share in 2017. Lantus is the top-selling drug in the country and occupies 49% market share, followed by Levemir, Tresiba, Toujeo, and Basaglar.
    The sale of Lantus is expected to decrease during the forecast period, due to the presence biosimilars Basaglar and Toujeo (which are the extended versions of Lantus).
    The other biosimilar of Lantus (insulin glargine) is Lusduna from Merck, which was tentatively approved by the FDA in the United States. However, despite a favorable nod from the FDA, Merck decided to discontinue Lusduna because of “anticipated pricing and cost of production”.
    Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2019-2024) due to its ultra-long-acting effect. The levemir segment is decreasing due to the switch of patients to Tresiba.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Basal Insulin (Long-Acting Insulin) create from those of established entities?

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999763

    Detailed TOC of Basal Insulin (Long-Acting Insulin) Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Product Type
    5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.1.1.1 Lantus
    5.1.1.2 Levemir
    5.1.1.3 Toujeo
    5.1.1.4 Tresiba
    5.1.1.5 Basaglar
    5.1.1.6 Insulin Glargine Biosimilars
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume, 2012-2024)
    5.2.1.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.1.2 Canada (Value and Volume, 2012-2024)
    5.2.1.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
    5.2.1.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume, 2012-2024)
    5.2.2.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.2 Germany (Value and Volume, 2012-2024)
    5.2.2.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.3 Italy (Value and Volume, 2012-2024)
    5.2.2.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.4 Spain (Value and Volume, 2012-2024)
    5.2.2.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
    5.2.2.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.6 Russia (Value and Volume, 2012-2024)
    5.2.2.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
    5.2.2.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume, 2012-2024)
    5.2.3.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.3.2 Brazil (Value and Volume, 2012-2024)
    5.2.3.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
    5.2.3.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume, 2012-2024)
    5.2.4.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.2 South Korea (Value and Volume, 2012-2024)
    5.2.4.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.3 China (Value and Volume, 2012-2024)
    5.2.4.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.4 India (Value and Volume, 2012-2024)
    5.2.4.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.5 Australia (Value and Volume, 2012-2024)
    5.2.4.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.6 Vietnam (Value and Volume, 2012-2024)
    5.2.4.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.7 Malaysia (Value and Volume, 2012-2024)
    5.2.4.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.8 Indonesia (Value and Volume, 2012-2024)
    5.2.4.8.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.9 Philippines (Value and Volume, 2012-2024)
    5.2.4.9.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.10 Thailand (Value and Volume, 2012-2024)
    5.2.4.10.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
    5.2.4.11.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
    5.2.5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5.2 Iran (Value and Volume, 2012-2024)
    5.2.5.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5.3 Egypt (Value and Volume, 2012-2024)
    5.2.5.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5.4 Oman (Value and Volume, 2012-2024)
    5.2.5.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5.5 South Africa (Value and Volume, 2012-2024)
    5.2.5.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012-2024)
    5.2.5.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk AS
    7.1.2 Sanofi Aventis
    7.1.3 Eli Lilly
    7.1.4 Biocon
    7.1.5 Julphar
    7.1.6 Exir
    7.1.7 SEDICO
    7.1.8 Wockhardt
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk AS
    7.2.2 Sanofi Aventis
    7.2.3 Eli Lilly
    7.2.4 Others

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global High Pressure Commercial Toilet Market Share, Size 2019 Movements by Trend Analysis, Progression Status, Revenue Expectation to 2024 | Research Report by Industry Research Biz

    Bovine Serum Albumin Market 2019 – Business Revenue, Future Growth, Trends Plans, Top Key Players, Business Opportunities, Industry Share, Global Size Analysis by Forecast to 2026 | Industry Research Biz

    Display Panel Market Growth by Manufacturers, Regions, Type and Application, Market Size, Forecast Analysis to 2025

    Prenatal Vitamin Supplements Market 2019-2022 Offers a Detailed Study on Development and Market Trends Adopted by Competitors